Colofac

Critical Warnings, Legal Status & Patient Protection (Safety First)

Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available In Australia: Colofac® — tablets 135 mg in blister packs of 30 or 500.
• ATC Code: A03AA04 — drugs for functional gastrointestinal disorders, synthetic anticholinergics, esters with tertiary amino group.
• Forms & Dosages: 135 mg tablets (1 tablet three times daily); 200 mg prolonged‑release capsules (1 capsule twice daily); oral liquid form for swallowing difficulties.
• Manufacturers In Australia: Mylan Australia (part of Viatris) is a major local supplier.
• Registration Status In Australia: Registered with the TGA as a prescription-only medicine.
• OTC / Rx Classification: Prescription-only in Australia; OTC availability applies in some other countries only.

Worried about whether Colofac is safe for you?

Colofac (mebeverine) is TGA-registered in Australia as a prescription-only medicine.

Prescribers and pharmacists must screen for absolute contraindications such as hypersensitivity and paralytic ileus, and note relative cautions including pregnancy, breastfeeding, severe liver or kidney impairment, and acute porphyrias.

Use the following checklist at point of care: allergies, current medicines, pregnancy or breastfeeding status, known hepatic or renal disease, and symptoms suggesting an acute abdomen.

Patient Protections: Pharmacist counselling is required at supply.

Keep the original blister pack, store below 25°C and protect from moisture and light, and keep out of reach of children.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Elderly patients usually use the standard adult dose unless frailty or comorbidities suggest caution.

Children under 10 years are generally not recommended to take mebeverine because safety and efficacy are not established.

Pregnancy and breastfeeding are relative cautions; avoid unless prescriber judges benefits to outweigh risks and documents consent.

Patients with severe liver or kidney impairment need careful assessment since clinical data are limited.

Always exclude acute structural causes of severe abdominal pain before starting mebeverine.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Some people report very rare central nervous system effects such as dizziness, drowsiness or blurred vision.

Advise caution with driving or operating heavy machinery until the individual knows how they respond.

If the patient holds a commercial licence or works at height, recommend checking with employer, prescriber or pharmacist before resuming duties.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Usually yes, but avoid driving if you feel dizzy, sleepy or visually impaired.

Check with your prescriber or pharmacist if you drive commercially or work at heights.

Usage Basics: INN, Brands And Legal Classification

INN And Australian Brands

The international nonproprietary name (INN) is mebeverine.

In Australia and New Zealand the brand Colofac® is marketed as 135 mg tablets in blister packs of 30 or 500.

Mylan Australia (part of Viatris) is a major local supplier for Colofac in Australia.

Legal Classification & Practical Implications

The TGA registers Colofac as prescription-only in Australia, which means it cannot be purchased over the counter without a valid prescription.

PBS subsidy status can vary, so advise patients to check the PBS website or discuss cost with their prescriber.

• TGA: Therapeutic Goods Administration — Australia’s regulator for medicines and medical devices.
• PBS: Pharmaceutical Benefits Scheme — government subsidy program for some prescription medicines.
• Prescription-only: Medicine supplied only with a prescription from an authorised prescriber.

Point-of-care checklist for pharmacists: confirm prescription authenticity, advise on storage, counsel on missed dose and side effects, and document counselling in the patient record.

• Available Forms And Strengths: 135 mg tablet.
• Other Forms: 200 mg modified-release capsule (availability varies by country), oral liquid for swallowing difficulties.

Dosing Guide (Practical Regimens And Missed-Dose Advice)

Standard Regimens

Adults: 135 mg tablet three times daily is the standard regimen for IBS and non-specific gut spasm.

An alternative formulation is a 200 mg prolonged‑release capsule taken twice daily where available.

Treatment length varies with symptoms and often continues for weeks to months under supervision.

If there is no meaningful benefit after about two weeks, recommend medical review and reassessment of the management plan.

Adjustments For Comorbidities And Special Groups

Children under 10 years: not recommended due to lack of data.

Older people: standard adult dosing is usually appropriate but assess frailty and comorbidity; adjust clinical monitoring not dose unless advised.

Severe hepatic or renal impairment: use with caution because formal data are limited; document rationale and monitor.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless it is nearly time for the next dose.

Do not double up doses to make up for a missed one.

If in doubt, consult your pharmacist or prescriber.

• Seek Medical Review If: worsening or spreading abdominal pain, GI bleeding, persistent fever, persistent vomiting, or signs of obstruction.

Interaction Chart: Drugs, Food And Alcohol

Food, Alcohol And Typical Australian Diet Considerations

Colofac has no major food interactions listed in the product information.

Alcohol may worsen gastrointestinal symptoms and can add to central side-effects such as dizziness and drowsiness, so advise moderation.

Acknowledge local dietary triggers for IBS such as coffee, spicy foods and high‑FODMAP meals; these are likely to trigger symptoms independently of medication.

Common Drug Conflicts And Monitoring

Mebeverine demonstrates few significant drug interactions according to product data.

Rare issues include the potential for false-positive amphetamine results on some urine drug screens.

• Ask Patients To Declare: other antispasmodics, CNS depressants, drugs affecting GI motility, and recent antibiotics at consultation.
• Pharmacist Checklist: reconcile medicines at each dispensing and document any interactions or counselling given.

User Reports & Australian Trends (Patient Experience)

What patients tell pharmacists in Australia: many report reduced cramping and abdominal pain after starting mebeverine, but the onset and degree of benefit vary.

Side-effects are uncommon but reported ones include dizziness, headache, skin rash and mild GI upset.

Socioeconomic factors commonly influence decisions: price sensitivity, preference for pharmacist advice and use of online forums for peer experience.

Rural patients may rely more on community pharmacists and telehealth for e‑prescriptions, with mail-order delivery used to improve access.

• Clinician Tip: Be aware of reporting bias in anecdotal reviews, encourage structured symptom diaries, and document therapeutic response at 2–4 weeks.

Access & Purchase Options In Australia

Major Chains, Online Pharmacies And Telehealth

Typical retail sources include Chemist Warehouse, Priceline, TerryWhite Chemmart and independent community pharmacies.

Colofac is prescription-only via the TGA in Australia, and patients can obtain an e-prescription from telehealth and present it to an online pharmacy or local dispenser.

Community pharmacists in rural areas often support ongoing supply management and can arrange mail-order for remote patients.

Avoid unregulated overseas suppliers and encourage purchase through a reputable Australian pharmacy.

In our online pharmacy, Colofac is available without a prescription, with discreet delivery to Australia in 9-21 days.

• Pharmacist Checklist: validate prescription, counsel on storage and missed doses, advise on side-effects, and record counselling.

Mechanism Of Action & Pharmacology (Plain English + Clinical)

Simplified Explanation

Mebeverine is classified under ATC code A03AA04 and works as a synthetic anticholinergic acting locally on gut smooth muscle to relieve spasm and abdominal pain.

It tends to produce fewer classic systemic anticholinergic side-effects than agents such as dicyclomine or hyoscine.

Because mebeverine acts locally in the gut, it is generally perceived as having a lower anticholinergic burden.

Clinical Pharmacology Details

• ATC Code: A03AA04.
• INN: Mebeverine.
• Prolonged-Release: 200 mg MR capsules alter the plasma profile to allow twice-daily dosing where available.

Onset of benefit varies; some patients notice improvement within days while others need weeks.

Mebeverine is non-habit forming and has low interaction potential.

Clinicians should monitor symptom scores, watch for rare adverse events such as angle‑closure glaucoma, and document baseline assessments.

Indications & Off‑Label Use In Australian Practice

Approved Indications By TGA

The primary indication for Colofac is symptomatic relief of abdominal pain, cramps and bowel irregularity associated with irritable bowel syndrome and non‑specific gut spasm.

TGA registration confirms prescription-only status in Australia.

Off‑Label Uses & Pragmatic Clinical Practice

Off‑label uses may include functional gastrointestinal spasm in selected cases or adjunctive therapy for spastic colonic syndromes where other measures are insufficient.

• Prescriber Checklist For Off‑Label Use: exclude structural or acute causes, document informed consent, set a trial duration and outcome measures, and outline escalation and deprescribing plans.

Red flags requiring urgent review include severe unrelieved pain, gastrointestinal bleeding and systemic signs such as fever or hypotension.

Key Clinical Findings & Evidence Summary (Australia And International 2022–2026)

Clinical trial data support the use of mebeverine for symptom relief in IBS with an acceptable safety profile and fewer systemic anticholinergic effects than older antimuscarinics.

Recent trials focus on symptom-based endpoints and patient-reported outcomes rather than solely physiological measures.

Evidence gaps include limited paediatric data and scarce information on severe hepatic or renal impairment.

There is a need for contemporary head‑to‑head trials comparing mebeverine with peppermint oil and gut-directed psychological therapies.

Clinicians are advised to use validated IBS symptom scales during treatment trials to document response.

Alternatives Matrix (Comparators & PBS-Listed Options)

PBS-Listed Alternatives Comparison Table

Pros And Cons Checklist

• Match Symptom Pattern: spasm‑predominant IBS benefits most from antispasmodics.
• Consider Comorbidities: avoid higher anticholinergic burden in patients with glaucoma or urinary retention.
• Assess Cost And PBS Access: discuss subsidy and generic options with the patient.
• Factor Patient Preference: some prefer herbal options, others want a prescription medicine.

Colofac is often preferred when systemic anticholinergic effects are a concern.

Common Questions From Australian Pharmacy Consultations (FAQ-Style)

Is Colofac Addictive? No — mebeverine is non-habit forming.

How Long To Work? Some patients notice improvement in days, others need weeks; review if no benefit after about two weeks.

Can Children Take It? Not recommended for children under 10 years.

• Pharmacist Counselling Prompts: confirm diagnosis, review for red flags, discuss lifestyle triggers, provide a written action plan, and document counselling.

• Definitions: Prolonged‑release means the formulation releases drug slowly to allow less frequent dosing.
• IBS: Irritable bowel syndrome — a functional disorder causing abdominal pain and bowel habit change.
• Red Flag Symptoms: Severe or worsening pain, GI bleeding, weight loss, fever — urgent review needed.

Pharmacists should record education and a follow-up plan in the patient medication records.

Price & Access Comparison (Table + Checklist)

Pricing Snapshot And PBS Considerations

• Access Checklist For Patients: have a valid prescription, ask about generic options, check concession entitlements, and consider telehealth if GP access is limited.
• Rural Vs Metro: mail-order and pharmacist repeat prescriptions can help maintain continuity in remote areas; plan for weather-related shipping delays.

Registration, Regulation & Professional Responsibilities

TGA Approval And Reporting Obligations

Colofac (mebeverine) is registered with the Therapeutic Goods Administration as prescription-only in Australia.

Pharmacists and prescribers must report suspected adverse reactions via the TGA reporting systems and follow local professional standards.

PBS Subsidy, Prescribing Authority And E-Prescriptions

Check the PBS for subsidy updates and document diagnosis when prescribing if a subsidy is sought.

• Prescriber Checklist: document diagnosis, obtain informed consent for any off‑label use, set a review schedule, and report adverse drug reactions.
• After Dispensing: provide counselling, monitor for ADRs and arrange follow-up at 2–4 weeks to assess effectiveness.

Suggested record wording for clinicians: “Started mebeverine 135 mg TDS for presumed IBS spasm; advised on storage, side-effects and follow-up in 2 weeks.”

Storage, Transport & Household Handling (Australian Climate Focus)

Home Storage And Safety

Store Colofac in the original blister pack below 25°C, protect from moisture and light, and keep out of reach of children.

In hot, humid Australian summers avoid storing medicines in cars or bathrooms where temperatures exceed recommended limits.

Discard if tablets change appearance or the pack is past the expiry date, and return unused medicine via a pharmacy take-back program.

Pharmacy And Courier Handling

Pharmacies should pack medicines to avoid prolonged exposure to heat during transit.

• Mail-Order Checklist: check expiry dates, use insulated envelopes if extreme weather is expected, provide tracking and advise patients about delivery windows.

Guidelines For Proper Use & Pharmacist Counselling (Practical Script)

Australian Pharmacist Counselling Style & Patient Advice

Confirm the indication: “This medicine is for IBS or gut spasms and helps reduce cramping and pain.”

Explain dose: “Take 135 mg one tablet three times daily, or if using a 200 mg MR capsule take one capsule twice daily where available.”

Set expectations: “You may notice improvement in days but allow up to a few weeks; if no benefit after two weeks, seek review.”

List common side-effects and rare serious signs: “Possible dizziness, headache, skin rash; stop and seek help for severe allergic reactions or sudden eye pain/blurred vision.”

Missed dose advice: “Take as soon as you remember unless close to the next dose; do not double up.”

Storage reminder: “Keep in original blister pack below 25°C and out of reach of children.”

PBS And Safety-Net Advice

• Discuss cost, generic options and whether PBS subsidy may apply.
• Recommend a symptom diary and schedule review at 2–4 weeks to assess response.
• Provide a printed or electronic handout summarising dose, side-effects and red flags.

Delivery Across Australia